{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T15:58:15Z","timestamp":1786723095207,"version":"build-2736575974"},"reference-count":35,"publisher":"JLE","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.nephro.2021.03.002","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T13:32:04Z","timestamp":1620739924000},"page":"180-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Screening for Fabry disease in male patients with end-stage renal disease in western France"],"prefix":"10.1684","volume":"17","author":[{"given":"C.","family":"Vigneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-007X","authenticated-orcid":false,"given":"D.P.","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Larmet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hourmant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2021.03.002_bib0180","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nephro.2021.03.002_bib0185","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s004390050292","article-title":"Fluorescence-assisted mismatch analysis (FAMA) for exhaustive screening of the alpha-galactosidase A gene and detection of carriers in Fabry disease","volume":"98","author":"Germain","year":"1996","journal-title":"Hum Genet"},{"key":"10.1016\/j.nephro.2021.03.002_bib0190","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1006\/bbrc.1999.0310","article-title":"Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches","volume":"257","author":"Germain","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.nephro.2021.03.002_bib0195","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cca.2014.08.002","article-title":"Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry","volume":"438","author":"Auray-Blais","year":"2015","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.nephro.2021.03.002_bib0200","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nephro.2021.03.002_bib0205","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nephro.2021.03.002_bib0210","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/STROKEAHA.114.006283","article-title":"Cerebrovascular involvement in Fabry disease: current status of knowledge","volume":"46","author":"Kolodny","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.nephro.2021.03.002_bib0215","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nephro.2021.03.002_bib0220","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.nephro.2021.03.002_bib0225","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype","volume":"63","author":"Nakao","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2021.03.002_bib0230","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jmg.2009.072116","article-title":"Screening for Fabry disease in high-risk populations: a systematic review","volume":"47","author":"Linthorst","year":"2010","journal-title":"J Med Genet"},{"key":"10.1016\/j.nephro.2021.03.002_bib0235","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jmedgenet-2017-105080","article-title":"Fabry Disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995-2017","volume":"55","author":"Doheny","year":"2018","journal-title":"J Med Genet"},{"key":"10.1016\/j.nephro.2021.03.002_bib0240","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ejmg.2015.10.014","article-title":"Enzymatic diagnosis of Fabry disease using a fluorometric assay on dried blood spots: an alternative methodology","volume":"58","author":"Caudron","year":"2015","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.nephro.2021.03.002_bib0245","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.nephro.2016.07.453","article-title":"REIN Registry. Ten-years trends in renal replacement therapy for end-stage renal disease in mainland France: lessons from the French Renal Epidemiology and Information Network (REIN) registry","volume":"13","author":"Vigneau","year":"2017","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.nephro.2021.03.002_bib0250","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.nephro.2021.03.002_bib0255","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/jmedgenet-2019-106467","article-title":"Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: a consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroup","volume":"57","author":"Germain","year":"2020","journal-title":"J Med Genet"},{"key":"10.1016\/j.nephro.2021.03.002_bib0260","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"European Expert Consensus statement on therapeutic goals in Fabry disease","volume":"124","author":"Wanner","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nephro.2021.03.002_bib0265","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.acvd.2019.01.002","article-title":"Fabry disease in cardiology practice: literature review and expert point of view","volume":"112","author":"Hag\u00e8ge","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.nephro.2021.03.002_bib0270","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.1666","article-title":"The benefits and challenges of family genetic testing in rare genetic diseases\u2013lessons from Fabry disease","author":"Germain","year":"2021","journal-title":"Mol Genet Genome Med"},{"key":"10.1016\/j.nephro.2021.03.002_bib0275","doi-asserted-by":"crossref","first-page":"103703","DOI":"10.1016\/j.ejmg.2019.103703","article-title":"Fabry disease caused by the GLA p.Phe113Leu (p.F113L) variant: natural history in males","volume":"63","author":"Oliveira","year":"2020","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.nephro.2021.03.002_bib0280","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ymgme.2019.07.012","article-title":"Founder effect of Fabry disease due to p.F113L mutation: clinical profile of a late-onset phenotype","volume":"129","author":"Azevedo","year":"2020","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nephro.2021.03.002_bib0285","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's disease with the pharmacologic chaperon migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2021.03.002_bib0290","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jmd2.12035","article-title":"Prevalence of Fabry disease in male dialysis patients: Argentinean screening study","volume":"48","author":"Frabasil","year":"2019","journal-title":"JIMD Report"},{"key":"10.1016\/j.nephro.2021.03.002_bib0295","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin Genet"},{"key":"10.1016\/j.nephro.2021.03.002_bib0310","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1806891","article-title":"Diagnostic utility of exome sequencing for kidney disease","volume":"380","author":"Groopman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2021.03.002_bib0305","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3389\/fgene.2019.01264","article-title":"Diagnostic yield of next-generation sequencing in patients with chronic kidney disease of unknown etiology","volume":"10","author":"de Haan","year":"2019","journal-title":"Front Genet"},{"key":"10.1016\/j.nephro.2021.03.002_bib0300","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ndt\/gfp554","article-title":"End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry","volume":"25","author":"Ortiz","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2021.03.002_bib0315","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/mgg3.389","article-title":"Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: a multicenter Fabry Registry study","volume":"6","author":"Germain","year":"2018","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.nephro.2021.03.002_bib0320","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00467-006-0176-5","article-title":"IgA nephropathy in two adolescent sisters heterozygous for Fabry disease","volume":"21","author":"Whybra","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nephro.2021.03.002_bib0325","doi-asserted-by":"crossref","first-page":"188","DOI":"10.5414\/CN108986","article-title":"Clinical and pathological characteristics of Fabry disease combined with IgA nephropathy in Chinese patients","volume":"87","author":"Yang","year":"2017","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2021.03.002_bib0330","doi-asserted-by":"crossref","first-page":"100454","DOI":"10.1016\/j.ymgmr.2019.100454","article-title":"The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts","volume":"19","author":"Germain","year":"2019","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.nephro.2021.03.002_bib0335","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ymgme.2018.09.007","article-title":"The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease\u00a0\u2013\u00a0A systematic literature review by a European panel of experts","volume":"126","author":"Germain","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nephro.2021.03.002_bib0340","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpt.1832","article-title":"Treatment of Fabry's disease with migalastat: outcome from a prospective observational multicenter study (FAMOUS)","volume":"108","author":"Lenders","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nephro.2021.03.002_bib0345","series-title":"Neurometabolic Hereditary Diseases of Adults.","first-page":"1","article-title":"Principle of human genetics and mendelian inheritance","author":"Germain","year":"2018"},{"key":"10.1016\/j.nephro.2021.03.002_bib0350","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jama.2020.11126","article-title":"Exome sequencing and clinical diagnosis","volume":"324","author":"Friedman","year":"2020","journal-title":"JAMA"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725521000596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725521000596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2021.03.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T14:52:07Z","timestamp":1741186327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725521000596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1769725521000596"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2021.03.002","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening for Fabry disease in male patients with end-stage renal disease in western France","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2021.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}